A female doctor in blue scrubs puts a plaster on the arm of a small girl wearing yellow dungarees, who looks down at the plaster.


Recent advances in genomics mean that increasing numbers of children and their families can benefit from genetic and genomic testing. Testing can provide new diagnoses, shape management decisions, guide treatment options and provide valuable information.

Paediatricians need a broad understanding of genomics to ensure that their patients have access to genomic tests at the right time. Clinical geneticists and paediatricians are finding new ways of working together to ensure more families benefit from the genomic technologies now available.

This page was launched as part of the month of genomics (March 2023) in collaboration with the Royal College of Paediatrics and Child Health. The resource is undergoing a period of review, and we welcome your feedback.

What do I need to know?

Why is genomics important in paediatrics?

Many genomic conditions affect early development, leading to congenital structural malformations and/or neurodevelopmental delay. This means that individuals with genomic conditions will commonly present in childhood.

By identifying a diagnosis, you can help patients and their families in a wide variety of ways. Some examples are outlined below.

Genomics in paediatrics: Family management, personalised treatment, information and support, and surveillance.

Information and support

Having a genomic diagnosis often allows the patient and their family – as well as other healthcare professionals – to learn more about their condition, understand the health implications in the short and long term, and access family support groups, which may be helpful from both an emotional and an educational perspective. Support groups often inform their members about developments in the field, including research and clinical trials.

Watch this short video about Beskida and Arvin’s experience of receiving a genomic diagnosis.


Some paediatric genomic conditions are associated with specific health complications, such as an increased risk of developing early childhood tumours. For some of these complications, specific surveillance guidelines have been developed and published; this means that if the genomic condition is diagnosed early on, the child will have timely access to a condition-specific surveillance programme that could improve their healthcare outcomes by identifying and enabling management of complications (which may include personalised treatments) at an early stage.

Personalised treatment

In some cases, a genomic diagnosis provides access to personalised treatment. Some examples of this are outlined below.

  • The use of commonly-used drugs proven to be particularly effective in a specific genomic condition. For example, the anticonvulsant retigabine (ezogabine) has particular efficacy in treating epilepsy caused by loss-of-function variants in the KCNQ2 gene.
  • The avoidance of certain medications. For example, some babies (1 in 500) are born with a particular genetic variant that means that administering the antibiotic gentamicin will cause irreversible hearing loss; however, new technologies have enabled clinicians to test for this genetic variant with a single cheek swab, which has a 15-minute turnaround time for results and means that use of gentamicin can be avoided where necessary.
  • The use of targeted therapies – many of which are in development – such as enzyme replacements, dietary restrictions or gene therapies. For example, patients with spinal muscular atrophy are now benefiting from treatment with nusinersen (widely marketed as Spinraza), a drug that is delivered directly to the central nervous system to target an underlying cause of motor neuron degeneration. Other similar treatments are also becoming more widely available in the UK.

Family management and reproductive choices

Because we share some of our DNA with people to whom we are genetically related, genomic conditions can have implications for our family members. This means that we must consider the inheritance pattern of any genomic diagnosis. It may be appropriate to offer parental testing, which helps to clarify any inheritance patterns and potential risks to immediate family members. For some conditions, it may be appropriate to offer cascade testing to the wider family.

Where there is a significant chance of future pregnancies being affected by the same genomic condition, some couples may wish to make complex, personal reproductive choices that may include a normal pregnancy (sometimes with additional scans or screening), use of donated sperm, egg and/or embryo, adoption, prenatal diagnosis or pre-implantation genetic diagnosis (PGD). Prenatal diagnosis is usually performed through chorionic villus sampling between 11 and 14 weeks of pregnancy. PGD is an IVF-based technique in which embryos are screened and only those without the familial genomic variant are transferred into the womb. In these scenarios, your role as a paediatrician would be to refer your patients to the appropriate specialist team – be it genetic counselling, fetal and women’s health or clinical genetics.

Finally, children with a genomic condition may be anxious about and want to discuss the implications of their diagnosis for any future children they themselves may have. An understanding of the inheritance patterns of genomic conditions will help you, as a paediatrician, to have those conversations with affected children.

What happens when genomic tests are inconclusive?

Many families will not receive a diagnosis through initial genomic testing. Trying to find the genomic variant responsible for a condition or syndrome is difficult, and sometimes it’s not possible: we are still limited by technology and our current knowledge base. When requesting genomic testing for a child, there are some important things for clinicians to know and do to help maximise the chance that a diagnosis will be identified. You can find out more about this in our dedicated resource.

Bear in mind that a normal genomic test does not rule out a genomic cause. Where a diagnosis is not identified, it is important to consider whether any further genomic testing would be beneficial. In cases in which no further genomic testing is currently available, it is important to remind families that it may be available in the future. It is also important to support families who do not receive a diagnosis by, for example, signposting them to patient support groups such as SWAN UK, a network run by Genetic Alliance UK. You can find out more about how to support families without a diagnosis in our rare disease education hub.

Watch this short video about Claudia and Trent, whose lives have been affected by an unidentified syndrome.

How can genomics be applied in paediatrics?

The number of ways in which genomics can be applied in paediatrics will only increase with time. Take a look at the diagram below to find out some of the ways in which genomics is already being used to improve paediatric patient outcomes.

Genomic applications: Pharmacogenomics (avoidance of harmful side-effects, knowing which drugs work best); Common disease (polygenic risk scores, screening, personalised advice); Single-gene disorders (diagnosis, management (including wider family)); Cancer (informing treatment options, identifying those at risk, screening); Infectious disease (identifying pathogens, monitoring outbreaks, supporting public health strategies).

What is my role as a paediatrician?

Below are just a few examples of the ways in which paediatricians can play a part in the development of genomic medicine across the NHS.

Facilitating genomic testing

Many paediatricians have been ordering genomic tests and managing results for years. For others, genomic testing may be completely new. Whatever your background, now is a good time to develop your skills in this area because the landscape of genomics is changing rapidly. For example, the National Genomic Test Directory is currently expanding the number of genomic tests available, and increasing your understanding of the latest genomic technologies and available tests can help you identify more patients who could benefit from testing.

Seeking informed consent

Paediatricians are increasingly ordering more complex genomic tests. It is therefore important to have a good understanding of the potential implications of testing, so that informed consent can be sought. This should be documented as part of a record of discussion.

Understanding a genomic test report

Once you have requested a genomic test and it has been carried out, the results will be analysed by clinical scientists in the genomic laboratory and a report will be produced. The responsibility for interpreting the implications of the report and communicating them to the patient and their family will sit with you, as the clinician who requested the test – though support will be available from clinical genetics specialists, and there may be local multi-disciplinary team (MDT) meetings at which you can discuss the results. To learn more about reading, understanding and communicating genomic test reports, watch our video tutorial.

While some genomic test reports may be relatively simple, others can be more complex. For example, a variant of uncertain significance may have been identified – that is, a variant for which there is insufficient data to determine whether it is causative of or contributing towards the patient’s clinical presentation. Rarely, an incidental or secondary finding may be identified that describes a genomic variant that is causative of disease (for example, a cancer predisposition syndrome), but not of the patient’s clinical presentation. Most variants of uncertain significance require a referral to a clinical genetics team.

Watch this video to learn more about variants of uncertain significance.

Managing a genomic diagnosis

Genomic testing has become more important in the acute management of some patients. The availability of broader and more rapid tests means that rare diagnoses can be identified in a timely manner, often with significant management implications.

Genomic discoveries are also being made in children with chronic and complex conditions, providing answers for families and healthcare professionals and clarifying the need for surveillance or referrals to the wider MDT.

As genomics becomes more mainstream, paediatricians will be taking more of a leadership role in the continuity of care of children with genomic conditions.

Working with genomics specialists

Paediatricians and clinical geneticists work closely in the management of rare genomic conditions in children. A referral to clinical genetics is indicated in many cases: for instance, cases in which a genomic diagnosis is suspected but testing has not identified one, or where further information and family testing for a new genomic diagnosis is required. In addition, MDTs that include clinical geneticists and paediatricians are increasingly being established; these MDTs provide a forum to discuss management of a genomic diagnosis, the interpretation of a genomic result or the appropriateness of a potential referral.

Supporting research

All the advances in genomics that we are now witnessing result from research. Research continues to support these advances, and will result in new genomic applications that improve the lives of children. Paediatricians can support their patients to take part in research by, for example, giving patients who are undergoing whole genome sequencing the option to submit their anonymised data to the National Genomic Research Library.

Genomics in practice: Bardet-Biedl syndrome

  • Antenatally, George was found to have an echogenic kidney (a kidney that appears bright in an ultrasound, indicating a possible condition). He was also born with an extra fifth digit (a condition known as polydactyly), and was consequently referred to the clinical genetics team.
  • When George was reviewed by the clinical genetics team as a baby, results of microarray testing and a postnatal renal ultrasound scan were both normal.
  • George was followed up by the clinical genetics team until the age of two. There were no further suspicions of a genetic disorder, so he was discharged back to paediatric care, where he was later managed for developing obesity and mild learning difficulties.
  • Due to evolving genomic technologies, George was then recruited into a research study into early-onset obesity by his paediatrician.
  • Two years later, the research study found two variants in George’s BBS5 gene, indicating a diagnosis of autosomal recessive Bardet-Biedl syndrome (BBS).
  • As well as presenting a cause for George’s polydactyly, obesity and learning difficulties, this new diagnosis had important implications for his management and prognosis. Sadly, most individuals with BBS become blind by their second or third decade of life.
  • George was referred back to the clinical genetics team for further support and counselling about the condition, while his paediatrician made clinical referrals to the ophthalmology, audiology, endocrinology and renal teams for surveillance of his syndromic manifestations.

Four types of genomic testing explained

Learn more about some of the different types of genomic tests available and how they are used to help patients

Learning opportunities

Teaching aids

Clinical resources

Identifying patients

Having a family history in a common condition, such as heart disease or diabetes, can be an important risk factor. For rare, inherited conditions, a genetic family tree can help to inform testing, surveillance, treatment and management strategies.

Activity: Taking and drawing a genetic family history

Equip yourself with the knowledge and skills to construct a genetic pedigree.

Activity: Recognising the clinical clues of a genetic condition

Familiarise yourself with the clinical features of a range of genetic conditions

Communicating with patients

With genomics increasingly being used in routine NHS care, along with the rise of direct-to-consumer testing, health professionals are more likely than ever to be talking to their patients about genomics.

Activity: Returning genomic test results to patients

There are a range of factors to consider when returning genomic results to patients, based on whether there is a confirmed diagnosis, an uncertain result or a negative result.

Latest updates

Recent articles

3D molecule

Rethinking insurance and genomic testing: the evidence

The DHSC's recent call for evidence received 57 responses from organisations and individuals, who voiced concerns and offered suggestions for future amendments
A doctor sits in a chair with a clipboard on his lap and a pen in his hand. He is mid-conversation with the patient opposite him, who sits up on a hospital bed and leans slightly forward.

New in GeNotes: Cardiology launches today!

Developed by clinical experts for cardiologists working across the NHS, this brand-new GeNotes collection is the latest specialty to be added to the flagship genomics education resource.
An illustrated group of people, featureless and in multiple bright colours.

Mind the gap: Five initiatives to boost genomic data diversity

White-ancestry genomes dominate genomic projects; here are five notable biobanks recruiting from under-represented populations to bridge the genomic gap

Upcoming events

Last updated on 8th March, 2023